Literature DB >> 22536753

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010.

M Colafigli1, C Torti, E M Trecarichi, L Albini, A Rosi, V Micheli, N Manca, G Penco, B Bruzzone, G Punzi, P Corsi, G Parruti, P Bagnarelli, L Monno, A Gonnelli, R Cauda, S Di Giambenedetto.   

Abstract

Prevalence and predictors of transmitted drug resistance (TDR), defined as the presence of at least one WHO surveillance drug resistance mutation (SDRM), were investigated in antiretroviral-naïve HIV-1-infected patients, with a genotypic resistance test (GRT) performed ≤6 months before starting cART between 2000 and 2010. 3163 HIV-1 sequences were selected (69% subtype B). Overall, the prevalence of TDR was 12% (13.2% subtype B, 9% non-B). TDR significantly declined overall and for the single drug classes. Older age independently predicted increased odds of TDR, whereas a more recent GRT, a higher HIV-RNA and C vs. B subtype predicted lower odds of TDR.
© 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22536753      PMCID： PMC6029625          DOI： 10.1111/j.1469-0691.2012.03847.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  11 in total

1.  The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.

Authors:  Linda Harrison; Hannah Castro; Patricia Cane; Deenan Pillay; Clare Booth; Andrew Phillips; Anna Maria Geretti; David Dunn
Journal:  AIDS       Date:  2010-07-31       Impact factor: 4.177

2.  Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.

Authors:  L Bracciale; M Colafigli; M Zazzi; P Corsi; P Meraviglia; V Micheli; R Maserati; N Gianotti; G Penco; M Setti; S Di Giambenedetto; L Butini; A Vivarelli; M Trezzi; A De Luca
Journal:  J Antimicrob Chemother       Date:  2009-07-16       Impact factor: 5.790

3.  Transmitted HIV Type 1 drug resistance and Non-B subtypes prevalence among seroconverters and newly diagnosed patients from 1992 to 2005 in Italy.

Authors:  Chiara Riva; Alessia Lai; Ilaria Caramma; Stefano Corvasce; Michela Violin; Lorenzo Dehò; Francesca Prati; Cristina Rossi; Maria Chiara Colombo; Amedeo Capetti; Marco Franzetti; Valeria Rossini; Giuseppe Tambussi; Massimo Ciccozzi; Barbara Suligoi; Cristina Mussini; Giovanni Rezza; Claudia Balotta
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

4.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

5.  Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

Authors:  Roberto Ortiz; Edwin Dejesus; Homayoon Khanlou; Evgeniy Voronin; Jan van Lunzen; Jaime Andrade-Villanueva; Jan Fourie; Sandra De Meyer; Martine De Pauw; Eric Lefebvre; Tony Vangeneugden; Sabrina Spinosa-Guzman
Journal:  AIDS       Date:  2008-07-31       Impact factor: 4.177

6.  Class-sparing regimens for initial treatment of HIV-1 infection.

Authors:  Sharon A Riddler; Richard Haubrich; A Gregory DiRienzo; Lynne Peeples; William G Powderly; Karin L Klingman; Kevin W Garren; Tania George; James F Rooney; Barbara Brizz; Umesh G Lalloo; Robert L Murphy; Susan Swindells; Diane Havlir; John W Mellors
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

7.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Authors:  Jeffrey L Lennox; Edwin DeJesus; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Daniel S Berger; Jing Zhao; Xia Xu; Angela Williams-Diaz; Anthony J Rodgers; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar
Journal:  Lancet       Date:  2009-08-03       Impact factor: 79.321

8.  Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Authors:  Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetchotisakd; Jorge Corral; Neal David; Graeme Moyle; Marco Mancini; Lisa Percival; Rong Yang; Alexandra Thiry; Donnie McGrath
Journal:  Lancet       Date:  2008-08-23       Impact factor: 79.321

9.  Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications.

Authors:  C Torti; G Lapadula; I Izzo; G Brindicci; G Labbate; E Quiros-Roldan; I Diallo; F Gargiulo; F Castelnuovo; A Calabresi; G Carosi; N Manca; L Monno
Journal:  Epidemiol Infect       Date:  2010-01-29       Impact factor: 2.451

10.  Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs.

Authors:  Claudia Alteri; Valentina Svicher; Caterina Gori; Roberta D'Arrigo; Massimo Ciccozzi; Francesca Ceccherini-Silberstein; Marina Selleri; Stefano Aviani Bardacci; Massimo Giuliani; Paola Elia; Paola Scognamiglio; Roberta Balzano; Nicoletta Orchi; Enrico Girardi; Carlo Federico Perno
Journal:  BMC Infect Dis       Date:  2009-07-16       Impact factor: 3.090
View more
  10 in total

1.  Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia.

Authors:  Praphan Phanuphak; Sunee Sirivichayakul; Awachana Jiamsakul; Somnuek Sungkanuparph; Nagalingeswaran Kumarasamy; Man Po Lee; Thira Sirisanthana; Pacharee Kantipong; Christopher Lee; Adeeba Kamarulzaman; Mahiran Mustafa; Rossana Ditangco; Tuti Merati; Winai Ratanasuwan; Thida Singtoroj; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

2.  Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013.

Authors:  Suzanne M McCluskey; Guinevere Q Lee; Kimia Kamelian; Annet Kembabazi; Nicholas Musinguzi; Mwebesa B Bwana; Conrad Muzoora; Jessica E Haberer; Peter W Hunt; Jeffrey N Martin; Yap Boum; David R Bangsberg; P Richard Harrigan; Mark J Siedner
Journal:  AIDS Patient Care STDS       Date:  2018-07       Impact factor: 5.078

3.  Short communication: Transmitted HIV drug resistance in antiretroviral-naive pregnant women in north central Nigeria.

Authors:  Godwin E Imade; Atiene S Sagay; Beth Chaplin; Philippe Chebu; Jonah Musa; Jonathan Okpokwu; Donald J Hamel; Ishaya C Pam; Oche Agbaji; Jay Samuels; Seema Meloni; Jean-Louis Sankale; Prosper Okonkwo; Phyllis Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-22       Impact factor: 2.205

4.  First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter study.

Authors:  Fabia Zu Knyphausen; Ramona Scheufele; Claudia Kücherer; Klaus Jansen; Sybille Somogyi; Stephan Dupke; Heiko Jessen; Dirk Schürmann; Osamah Hamouda; Karolin Meixenberger; Barbara Bartmeyer
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

5.  National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014.

Authors:  Andrea Hauser; Alexandra Hofmann; Kirsten Hanke; Viviane Bremer; Barbara Bartmeyer; Claudia Kuecherer; Norbert Bannert
Journal:  Euro Surveill       Date:  2017-01-12

Review 6.  Primary HIV Infection: Clinical Presentation, Testing, and Treatment.

Authors:  Aurélia Henn; Clara Flateau; Sébastien Gallien
Journal:  Curr Infect Dis Rep       Date:  2017-09-07       Impact factor: 3.663

7.  Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland.

Authors:  Miłosz Parczewski; Anna Urbańska; Katarzyna Maciejewska; Magdalena Witak-Jȩdra; Magdalena Leszczyszyn-Pynka
Journal:  J Int AIDS Soc       Date:  2014-04-17       Impact factor: 5.396

8.  Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy.

Authors:  Marco Franzetti; Michela Violin; Andrea Antinori; Andrea De Luca; Francesca Ceccherini-Silberstein; Nicola Gianotti; Carlo Torti; Stefano Bonora; Maurizio Zazzi; Claudia Balotta
Journal:  BMC Infect Dis       Date:  2014-07-18       Impact factor: 3.090

9.  Increasing Prevalence of HIV-1 Transmitted Drug Resistance in Portugal: Implications for First Line Treatment Recommendations.

Authors:  Marta Pingarilho; Victor Pimentel; Isabel Diogo; Sandra Fernandes; Mafalda Miranda; Andrea Pineda-Pena; Pieter Libin; Kristof Theys; M Rosário O Martins; Anne-Mieke Vandamme; Ricardo Camacho; Perpétua Gomes; Ana Abecasis
Journal:  Viruses       Date:  2020-10-30       Impact factor: 5.048

Review 10.  Aging with HIV: a practical review.

Authors:  Sandra Wagner Cardoso; Thiago Silva Torres; Marilia Santini-Oliveira; Luana Monteiro Spindola Marins; Valdiléa Gonçalves Veloso; Beatriz Grinsztejn
Journal:  Braz J Infect Dis       Date:  2013-05-25       Impact factor: 3.257
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.